Company intelligence / Profile preview

MBL

Japan
Ownership
Private
Employees
~400
Development stage
Other
01

Overview

MBL is a leading Japanese company commercializing in vitro diagnostics and research reagents—primarily focusing on autoimmune, cancer, gynecological, and infectious diseases—offering antibody-based diagnostics, companion diagnostics, and immune monitoring reagents used worldwide.

Therapeutic areas
ImmunologyInfectious DiseasesOncologyNeurologyWomen's Health
Modalities
AntibodyRecombinant proteinMonoclonal antibodyFluorescent proteinELISA kitMHC multimer
Industry
Molecular Diagnostics
02

Partnerships

JSR Life Sciences companiesImmunoPrecise Antibodies (IPA)Agappe (technology transfer partnership)

Beyond the preview

Go deeper on MBL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call